enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves new COPD drug developed by firm in Raleigh ... - AOL

   www.aol.com/news/fda-approves-copd-drug...

   A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade.

3. The Most Exciting New Advances in Managing COPD - AOL

   www.aol.com/most-exciting-advances-managing-copd...

   For people with COPD—and their care providers—the future looks bright. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Mail ...

4. Icenticaftor - Wikipedia

   en.wikipedia.org/wiki/Icenticaftor

   Icenticaftor (development code QBW251) is a drug candidate for the treatment of chronic obstructive pulmonary disease (COPD) [1] [2] and cystic fibrosis. [3] [4] The drug is being developed by Novartis.

5. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...

6. How To Be Active in Your Treatment Journey With COPD - AOL

   www.aol.com/active-treatment-journey-copd...

   Eating heart-healthy foods, having more frequent, smaller meals instead of three bigger meals, and minimizing foods that cause bloating or gas, which can make breathing more difficult, all play a ...

7. Global Initiative for Chronic Obstructive Lung Disease

   en.wikipedia.org/wiki/Global_Initiative_for...

   [1] [2] They have organized the annual awareness day, World COPD Day, every November since 2002. [3] This organization issues recommendations for the treatment of chronic obstructive pulmonary disease and related medical conditions. GOLD issued its first formal recommendations in 2001. [2]